| Revision as of 16:27, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,084 edits Saving copy of the {{drugbox}} taken from revid 458638000 of page Yttrium_(90Y)_clivatuzumab_tetraxetan for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 16:42, 12 November 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers174,413 edits Adding local short description: "Pharmaceutical drug", overriding Wikidata description "chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
|
{{Short description|Pharmaceutical drug}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{DISPLAYTITLE:Yttrium (<sup>90</sup>Y) clivatuzumab tetraxetan}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 458636504 |
|
| verifiedrevid = 470634923 |
|
| type = mab |
|
| type = mab |
|
| image = |
|
| image = |
| Line 10: |
Line 12: |
|
| source = zu/o |
|
| source = zu/o |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| Drugs.com = |
|
| Drugs.com = |
|
| MedlinePlus = |
|
| MedlinePlus = |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
|
| pregnancy_category= |
|
| pregnancy_category= |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
|
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> |
| Line 24: |
Line 23: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 33: |
Line 31: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number_Ref = {{cascite|changed|??}} |
|
| CAS_number = <!-- blanked - oldvalue: 943976-23-6 --> |
|
| CAS_number = 943976-23-6 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII = 2L271110ED |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 42: |
Line 41: |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
|
| C=6496 | H=9952 | N=1716 | O=2014 | S=44 |
| ⚫ |
<!--Chemical data--> |
|
|
| C = 6496 |
|
|
| H = 9952 |
|
|
| N = 1716 |
|
|
| O = 2014 |
|
|
| S = 44 |
|
|
| molecular_weight = 145.7 kDa |
|
|
}} |
|
}} |
|
|
|
|
|
'''Yttrium (<sup>90</sup>Y) clivatuzumab tetraxetan''' (trade name '''hPAM4-Cide''') is a humanized monoclonal ] designed for the treatment of ].<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref> The antibody part, '''clivatuzumab''' (targeted at ]), is conjugated with ], a ] for ],<ref></ref> a ] which destroys the tumour cells. |
|
|
|
|
|
The drug was developed by Immunomedics, Inc. |
|
|
|
|
|
In March 2016 the phase III ''PANCRIT-1'' trial in metastatic pancreatic cancer was terminated early due to lack of improvement of ].<ref></ref> |
|
|
|
|
|
== References == |
|
|
<references/> |
|
|
|
|
|
{{monoclonals for tumors}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{Nuclear-med-stub}} |
|
|
{{monoclonal-antibody-stub}} |
|
|
{{antineoplastic-drug-stub}} |